ES2128055T3 - Vacuna contra infecciones de bacterias gram-negativas. - Google Patents

Vacuna contra infecciones de bacterias gram-negativas.

Info

Publication number
ES2128055T3
ES2128055T3 ES95917557T ES95917557T ES2128055T3 ES 2128055 T3 ES2128055 T3 ES 2128055T3 ES 95917557 T ES95917557 T ES 95917557T ES 95917557 T ES95917557 T ES 95917557T ES 2128055 T3 ES2128055 T3 ES 2128055T3
Authority
ES
Spain
Prior art keywords
gram
vaccine
lps
negative bacteria
against gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95917557T
Other languages
English (en)
Inventor
Apurba Bhattacharjee
Alan Cross
Erald Sadoff
Wendell Zollinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Army
Original Assignee
US Department of Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Army filed Critical US Department of Army
Application granted granted Critical
Publication of ES2128055T3 publication Critical patent/ES2128055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA VACUNA, EFECTIVA EN LA INDUCCION DE LA PRODUCCION DE ANTICUERPOS CON LOS QUE INMUNIZAR UN SEGUNDO SUJETO PASIVAMENTE CONTRA LA INFECCION POR BACTERIA GRAM-NEGATIVA Y PATOLOGIA EN LA QUE MEDIA LPS, COMPRENDE UN COMPLEJO POLIVALENTE NO COVALENTE FORMADO ENTRE LPS PURIFICADO, DESTOXIFICADO DERIVADO DE E. COLI Y PROTEINA DE MEMBRANA EXTERIOR PURIFICADA DERIVADA DE N. MENINGITIDIS. LA MISMA VACUNA TAMBIEN INMUNIZARA ACTIVAMENTE UN SUJETO HUESPED CONTRA LAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS Y PATOLOGIA EN LA QUE MEDIA LPS. ENTRE ESTAS INFECCIONES BACTERIANAS GRAM-NEGATIVAS CONTRA LAS QUE PROTEGE LA VACUNA SE INCLUYEN INFECCIONES DE MENINGOCO.
ES95917557T 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas. Expired - Lifetime ES2128055T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23040294A 1994-04-20 1994-04-20

Publications (1)

Publication Number Publication Date
ES2128055T3 true ES2128055T3 (es) 1999-05-01

Family

ID=22865082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95917557T Expired - Lifetime ES2128055T3 (es) 1994-04-20 1995-04-20 Vacuna contra infecciones de bacterias gram-negativas.

Country Status (9)

Country Link
US (3) US7025963B1 (es)
EP (1) EP0710118B1 (es)
AT (1) ATE173634T1 (es)
AU (1) AU2356095A (es)
DE (1) DE69506212T2 (es)
DK (1) DK0710118T3 (es)
ES (1) ES2128055T3 (es)
GR (1) GR3029477T3 (es)
WO (1) WO1995029662A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011440A4 (en) * 1997-05-16 2003-08-06 Medical Defense Tech Llc VACCINE AGAINST THE CORE OF LIPOPOLYSACCHARIDES
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
EP2261356A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
CN100338218C (zh) 1999-05-19 2007-09-19 启龙股份公司 组合式奈瑟球菌组合物
EP2975127A1 (en) * 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1248647E (pt) * 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9616116B2 (en) * 2005-10-24 2017-04-11 University Of Maryland, Baltimore Detoxified endotoxin immunogenic compositions and uses thereof
WO2007050606A2 (en) * 2005-10-24 2007-05-03 The University Of Maryland, Baltimore Detoxified endotoxin vaccine and adjuvant and uses thereof
WO2010027499A2 (en) * 2008-09-05 2010-03-11 University Of Massachusetts Medical School Methods, compositions and vaccines relating to neisseria meningitidis antibodies
US8258705B2 (en) * 2009-04-29 2012-09-04 Hubbell Incorporated Scotopically enhanced emergency light and control thereof
BR112012008682A2 (pt) 2009-10-12 2017-06-20 New Health Sciences Inc "dispositivo de depleção de oxigênio, e, método para remover oxigênio de células vermelhas do sangue."
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US9199016B2 (en) 2009-10-12 2015-12-01 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US8535421B2 (en) 2009-10-12 2013-09-17 New Health Sciences, Inc. Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities
US9339025B2 (en) 2010-08-25 2016-05-17 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
JP5859558B2 (ja) 2010-11-05 2016-02-10 ニュー・ヘルス・サイエンシーズ・インコーポレイテッドＮｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 赤血球の照射及び嫌気性保存
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
ES2742949T3 (es) 2011-08-10 2020-02-17 New Health Sciences Inc Dispositivo integrado de filtrado para el agotamiento de leucocitos, oxígeno y/o co2 y separación de plasma
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP3400960A1 (en) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
EP2961269B1 (en) 2013-02-28 2021-09-15 Hemanext Inc. Gas depletion device for blood products
CN105492021B (zh) 2013-09-08 2018-12-04 辉瑞公司 脑膜炎奈瑟氏球菌组合物及其方法
CN113694272A (zh) 2015-03-10 2021-11-26 希玛奈克斯特股份有限公司 氧减少一次性套件、装置及其使用方法
BR122022005103B1 (pt) 2015-04-23 2023-03-14 Hemanext Inc Dispositivo de armazenamento de sangue para armazenar sangue depletado de oxigênio e método para armazenar sangue depletado de oxigênio
EP3297641A4 (en) 2015-05-18 2019-02-06 New Health Sciences, Inc. METHODS FOR TOTAL BLOOD STORAGE AND CORRESPONDING COMPOSITIONS
ES2910948T3 (es) 2016-05-27 2022-05-17 Hemanext Inc Almacenamiento anaeróbico de sangre y procedimiento de inactivación de patógenos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB109688A (en) 1916-11-04 1917-09-27 Herbert Senior Vincent Improvements in Steam Jacketed Heating or Boiling Pans and like Receptacles.
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
IE66690B1 (en) * 1986-05-23 1996-01-24 Oread Pharmaceutical Inc Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock

Also Published As

Publication number Publication date
DE69506212D1 (de) 1999-01-07
US20060159702A1 (en) 2006-07-20
US7025963B1 (en) 2006-04-11
AU2356095A (en) 1995-11-29
ATE173634T1 (de) 1998-12-15
US7018636B1 (en) 2006-03-28
EP0710118B1 (en) 1998-11-25
DE69506212T2 (de) 1999-08-05
US7235644B2 (en) 2007-06-26
EP0710118A1 (en) 1996-05-08
WO1995029662A3 (en) 1995-11-30
GR3029477T3 (en) 1999-05-28
WO1995029662A2 (en) 1995-11-09
DK0710118T3 (da) 1999-08-09

Similar Documents

Publication Publication Date Title
ES2128055T3 (es) Vacuna contra infecciones de bacterias gram-negativas.
GB9513074D0 (en) Novel anigen
EA200100565A1 (ru) Новые стрептококковые антигены
EP1792994A3 (en) Vaccines of bacterial outer membrane vesicles
PT754050E (pt) Metodos e materiais contra bacterias gram-positivas
DE69533673D1 (de) Behandlung und prävention von helicobacter-infektionen
ES2070266T3 (es) Vacuna contra la infeccion por escherichia coli.
KR920703097A (ko) 스트렙토코커스 b군에 대한 백신 접합체
Anwar et al. Antibody response to acute Pseudomonas aeruginosa infection in a burn wound
Williams et al. Protein antigens of Staphylococcus epidermidis grown under iron-restricted conditions in human peritoneal dialysate
Ala'Aldeen et al. Immunogenicity and cross-reactivity of the 70-Kda iron-regulated protein of Neisseria meningitidis in man and animals
DK0776214T3 (da) Antibakterialt præparat indeholdende multimert alfa-lactalbumin
Tambawala et al. Continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis in a child: a rare case of peritonitis caused by sphingomonous paucimobilis
Rupp et al. Hemagglutination by Staphylococcus aureus strains responsible for human bacteremia or bovine mastitis
Barton et al. Further characterization of Renibacterium salmoninarum extracellular products
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
Lång et al. The maltose-inducible 43 kDa major outer membrane protein in Vibrio cholerae is immunogenic and common to different isolates
Ludovici et al. Column chromatography and cell culture assay of Pseudomonas aeruginosa toxin Z preparations
RU95120818A (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
Flancock The Role of the Cell Surface Components of Pseudomonas aeruginosain virulence
KILIAN 1. Bacterial interference with mucosal immunity
Baker Neutrophil bactericidal activity against Actinobacillus actinomycetemcomitans: The effects of antibiotics and the contribution of opsonins.
McGillivary et al. Finding a new way to calm the storm
MOFFATT NEW PRINCIPLES IN BACTERIAL IMMUNITY pROFESSOR Georges Dreyer of the partment of Pathology, in the University of Oxford, has recently published (British Journal of Experi
Hancock The Role of the Cell Surface Components of Pseudomonas aeruginosa in Virulence

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710118

Country of ref document: ES